BARRETT'S ESOPHAGUS 

Barrett’s Esophagus is associated with long-term gastro-esophageal reflux disease (GERD) and is a risk factor for esophageal cancer. Current practice is to screen select patients who have multiple risk factors for esophageal cancer and monitor those patients diagnosed with Barrett's Esophagus for development of precancerous change (dysplasia). Patients who are at higher risk of progressing to esophageal cancer may benefit from endoscopic therapy. 

ISDE endorsed and sponsored the following research:

• 2015 International Consensus of the Management of Benign Barrett’s (BOB CAT)
• 2012 Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process (BAD CAT)

Additional information can be found below.

• Prague classification of Barrett’s esophagus
• 2018 and 2012 guidelines from the American Society of Gastrointestinal Endoscopy
• 2016 guideline from the American College of Gastroenterology
• 2014 guideline from the British Society of Gastroenterology
• 2016 expert review and 2011 guideline from the American Gastroenterological Association

Barrett's Roundtable Discussion Series

Expert roundtable discussion on the management of Barrett’s Esophagus. Roundtable Series 4 is presented in three episodes covering screening and diagnosis, assessment, and endoscopic therapy.

Listen to an open dialogue between multi-disciplinary specialists and leaders in the field, recorded during the 16th World Congress for Esophageal Diseases in Vienna, Austria.

International Panelists:

• Vani Konda, Baylor University Medical Center, USA
• Gary Falk, University of Pennsylvania Perelman School of Medicine Philadelphia, USA
• Prateek Sharma, University of Kansas School of Medicine and VA Medical Center, USA
• Peter Siersema, Radboud University Medical Center, Netherlands
• Kenneth Wang, Mayo Clinic Rochester, USA